INVA Q3 2025 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M+20.4% YoY

Gross Profit

$82M76.1% margin

Operating Income

$35M32.1% margin

Net Income

$90M83.4% margin

EPS (Diluted)

$1.08

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$49M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$419M

Stockholders' Equity

$1.0B

Cash & Equivalents

$477M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$90M	+20.4%
Gross Profit	$82M	$80M	+3.2%
Operating Income	$35M	$50M	-30.5%
Net Income	$90M	$1M	+7312.0%

Revenue Segments

Royalty

$60M56%

Product

$47M44%

License And Other Revenue

$610,0001%